Who can participate?
Newly diagnosed acute lymphoblastic leukemia (ALL)
- Definitive evidence of BCR-ABL fusion (Philadelphia chromosome positive [PH+]) from an approved Children's Oncology Group (COG) cytogenetics laboratory
- Concurrent enrollment on COG-AALL03B1 (or a successor trial) AND a front-line COG ALL clinical trial (e.g., COG-AALL0232, COG-AALL0331, COG-AALL0434 or other front-line COG ALL clinical trial) required
- Received the first 2 weeks of induction therapy (days 1-14) as specified in the front-line COG ALL clinical trial
- Patients may NOT have received day 15 of induction therapy on the front-line COG ALL clinical trial prior to enrollment on this study
- No Down syndrome
What will happen in the study?
A total number of 195 patients will be enrolled on this study.
An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.